Kurzfassung

A study to evaluate Imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk Myelodysplastic Syndrome (MDS) that is relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment